SETD7

Histone-lysine N-methyltransferase SETD7 · Q8WTS6 · SETD7 on Sugi Atlas →

10,808 patent compounds predicted against SETD7, 6,902 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cyproheptadine (SCHEMBL4021)	1.00	7/20
Cyproheptadine (SCHEMBL41842)	0.96	7/20
Cyproheptadine (SCHEMBL571975)	0.79	7/20
SCHEMBL1436286	0.65	7/20
Erizepine (SCHEMBL2109749)	0.50	6/20
Pimethixene (SCHEMBL301596)	1.00	5/20
Pimethixene (SCHEMBL301225)	0.76	5/20
Pimethixene (SCHEMBL301226)	0.76	5/20
SCHEMBL490256	0.76	5/20
Clopipazan (SCHEMBL1816896)	0.76	5/20
Pizotyline (SCHEMBL44122)	0.73	5/20
Azanator (SCHEMBL2110669)	0.71	5/20
Maroxepin (SCHEMBL2108201)	0.69	5/20
SCHEMBL490515	0.68	5/20
SCHEMBL460277	0.66	5/20
Clopipazan (SCHEMBL120732)	0.64	5/20
SCHEMBL490143	0.64	5/20
SCHEMBL1917876	0.62	5/20
Pizotyline (SCHEMBL1000901)	0.58	5/20
Pizotyline (SCHEMBL1000902)	0.58	5/20

Clinical trials — most relevant to SETD7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma	PHASE1	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
The Efficacy of Allo-HSCT in ND HR-CBF-AML	nan	RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Specific Methylation Profiles in HNSCC	nan	RECRUITING
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SETD7 binder may also engage these)

Protein	Name	Similarity
Q8VHL1	—	0.993	Q8VHL1 →
Q4QQN5	—	0.977	Q4QQN5 →
Q6DHG0	—	0.966	Q6DHG0 →
Q5F415	—	0.922	Q5F415 →
Q8VE10	—	0.922	Q8VE10 →
Q7TSL3	—	0.921	Q7TSL3 →
Q9CZW5	—	0.920	Q9CZW5 →
A0MQH0	—	0.919	A0MQH0 →
P10868	—	0.919	P10868 →
Q5R8I6	—	0.919	Q5R8I6 →
O35969	—	0.919	O35969 →
NAA40	N-alpha-acetyltransferase 40	0.918	landscape →
Q8R418	—	0.918	Q8R418 →
Q6TUI4	—	0.918	Q6TUI4 →
NTRK3	NT-3 growth factor receptor	0.918	landscape →
Q75Q39	—	0.918	Q75Q39 →
Q9UPY3	—	0.917	Q9UPY3 →
Q5ZIT8	—	0.917	Q5ZIT8 →
Q6PC62	—	0.917	Q6PC62 →
Q9NUY8	—	0.917	Q9NUY8 →
Q7TPD1	—	0.917	Q7TPD1 →
Q14353	—	0.916	Q14353 →
Q86XK2	—	0.916	Q86XK2 →
Q9CQC8	—	0.915	Q9CQC8 →
Q25BN1	—	0.915	Q25BN1 →
Q6P1X5	—	0.915	Q6P1X5 →
Q28943	—	0.915	Q28943 →
Q0GGW5	—	0.915	Q0GGW5 →
Q1M199	—	0.915	Q1M199 →
Q8QZR7	—	0.915	Q8QZR7 →